| 摘要 |
Stable pharmaceutical formulations are provided comprising atorvastatin magnesium as active ingredient. The atorvastatin magnesium is preferably in crystallised form, fully crystallised or partially crystallised. The crystallised material may comprise one or more polymorphic forms, which have characterised powder X-ray diffraction spectra. |
